CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRATANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT #2 TO THE PROMOTION AGREEMENTThe Promotion Agreement • May 7th, 2024 • Siga Technologies Inc • Pharmaceutical preparations
This AMENDMENT #2 TO THE PROMOTION AGREEMENT (this “Amendment No. 2”) is entered into as of March 27, 2024, between SIGA TECHNOLOGIES, INC., a Delaware corporation (“SIGA”), and MERIDIAN MEDICAL TECHNOLOGIES, LLC (f/k/a Meridian Medical Technologies, Inc.), a Delaware limited liability company (“MMT”). SIGA and MMT are each referred to herein as a “Party” or collectively as the “Parties”.
AMENDMENT #1 TO THE PROMOTION AGREEMENTThe Promotion Agreement • May 7th, 2024 • Siga Technologies Inc • Pharmaceutical preparations
This AMENDMENT #1 TO THE PROMOTION AGREEMENT (“Amendment No. 1”) is entered into and made effective as of September 10, 2020 (the “Amendment No. 1 Effective Date”) between SIGA Technologies, Inc., a Delaware corporation, having an address at 31 East 62nd Street, New York, NY 10065 (“SIGA”), and Meridian Medical Technologies, Inc., a Pfizer company, and Delaware corporation, having an address at 6350 Stevens Forest Road, Suite #301, Columbia, MD 21046 (“MMT”). SIGA and MMT are each referred to herein as a “Party” or collectively as the “Parties.”
